Hematopoietic stem cell transplantation for hematological malignancies in Europe

被引:87
作者
Gratwohl, A [1 ]
Baldomero, H
Passweg, J
Frassoni, F
Niederwieser, D
Schmitz, N
Urbano-Ispizua, A
机构
[1] Kantonsspital, Dept Internal Med, Div Hematol, CH-4031 Basel, Switzerland
[2] Osped San Martino Genova, Bone Marrow Transplant Unit, Genoa, Italy
[3] Univ Hosp, Div Hematol & Oncol, Leipzig, Germany
[4] Klin St Georg, Hamburg, Germany
[5] Hosp Clin Barcelona, EBMT Secretariat, Barcelona, Spain
基金
新加坡国家研究基金会;
关键词
hematological malignancies; HSCT; transplant rates; evolution; donor type;
D O I
10.1038/sj.leu.2402896
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hematopoietic stem cell transplants (HSCTs) are considered the best treatment option for many hematological malignancies, and transplant numbers have increased five-fold during the last decade. Only a few controlled prospective studies are available, and different opinions prevail. Data from 118 167 HSCT (36% allogeneic, 64% autologous) collected within the EBMT activity survey from 1990 to 2001 were used to assess trends over time, transplant rates and coefficient of variation (CV) of transplant rates among European countries for acute myeloid leukemia (AML; 18.5%), acute lymphocytic leukemia (ALL; 12%), chronic myeloid leukemia (CML; 11.5%), myelodysplastic syndromes (MDS; 3%), lymphoproliferative disorders (LIPS; 36.3%) and multiple myeloma (MM ; 18.7%). Transplant rates increased in all countries and for all indications from 1990 to 2001 from 1.7-fold (CML) to 24.8-fold (MM). Transplant rates have declined for CML since 1999. Autologous HSCT are the preferred choice for LIPS and MM, allogeneic HSCT for ALL and myeloid malignancies. CVs of less than 50% suggest consensus for allogeneic HSCT in AML, ALL, CML, MDS and NHL, for autologous HSCT in LPS and MM. These data give an overview of the current status of HSCT for hematological malignancies in Europe and provide objective information for health-care providers and patient counselling.
引用
收藏
页码:941 / 959
页数:19
相关论文
共 44 条
[41]  
Uderzo Cornelio, 2002, Haematologica, V87, P47
[42]   Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe [J].
Urbano-Ispizua, A ;
Schmitz, N ;
de Witte, T ;
Frassoni, F ;
Rosti, G ;
Schrezenmeier, H ;
Gluckman, E ;
Friedrich, W ;
Cordonnier, C ;
Socie, G ;
Tyndall, A ;
Niethammer, D ;
Ljungman, P ;
Gratwohl, A ;
Apperley, J ;
Niederwieser, D ;
Bacigalupo, A .
BONE MARROW TRANSPLANTATION, 2002, 29 (08) :639-646
[43]   Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes [J].
Weisdorf, D ;
Bishop, M ;
Dharan, B ;
Bolwell, B ;
Cahn, JY ;
Cairo, M ;
Giralt, S ;
Klein, J ;
Lazarus, H ;
Litzow, M ;
Marks, D ;
McCarthy, P ;
Miller, C ;
Milone, G ;
Russell, J ;
Schultz, KR ;
Sierra, J ;
Wiernik, P ;
Keating, A ;
Loberiza, F ;
Kollman, C ;
Horowitz, M .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2002, 8 (04) :213-220
[44]   AUTOLOGOUS OR ALLOGENEIC BONE-MARROW TRANSPLANTATION COMPARED WITH INTENSIVE CHEMOTHERAPY IN ACUTE MYELOGENOUS LEUKEMIA [J].
ZITTOUN, RA ;
MANDELLI, F ;
WILLEMZE, R ;
DEWITTE, T ;
LABAR, B ;
RESEGOTTI, L ;
LEONI, F ;
DAMASIO, E ;
VISANI, G ;
PAPA, G ;
CARONIA, F ;
HAYAT, M ;
STRYCKMANS, P ;
ROTOLI, B ;
LEONI, P ;
PEETERMANS, ME ;
DARDENNE, M ;
VEGNA, ML ;
PETTI, MC ;
SOLBU, G ;
SUCIU, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (04) :217-223